Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase.
The substituted benzimidazoles are a new class of drugs with a unique antisecretory action. These agents have great potential for treatment of acid-peptic disease because they produce substantial, long-lasting inhibition of gastric acid secretion by inhibiting gastric H+,K+-ATPase in the gastric parietal cell. Clinical trials of omeprazole, a substituted benzimidazole, indicate that it is safe and effective for short-term treatment of patients with duodenal or gastric ulcer, and it is highly effective for long-term treatment of patients with Zollinger-Ellison syndrome.
D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy; D005744:Gastric Acid / Q000378:metabolism; D017506:H(+)-K(+)-Exchanging ATPase; D006801:Humans; D009853:Omeprazole; D010295:Parietal Cells, Gastric / Q000201:enzymology*; D010437:Peptic Ulcer / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000188:drug therapy; D015043:Zollinger-Ellison Syndrome / Q000188:drug therapy*
D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D000251:Adenosine Triphosphatases; D017506:H(+)-K(+)-Exchanging ATPase; D009853:Omeprazole